> Idorsia increased enrollment in clazosentan Japanese registration studies due to “a lower than anticipated number of events.” The action pushed back the readouts from trials of the treatment for vasospasm associated with aneurysmal subarachnoid hemorrhage. Statement
> DBV Technologies filed for FDA approval of its peanut allergy drug. Release (PDF)
> MC2 Therapeutics posted top-line phase 2 data on its treatment for moderate-to-severe dry eye. Statement
> Scancell revealed that the FDA has asked for more information before signing off on a clinical trial. Release
> BioLineRx shared data from its Keytruda combination trial. Statement
> Adaptimmune provided updated data from its ongoing MAGE-A10 and MAGE-A4 studies. Release